2026 Lipid Guidelines Beyond Statins:  Non- Statin Agents to Manage Dyslipidemias - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

2026 Lipid Guidelines Beyond Statins:  Non- Statin Agents to Manage Dyslipidemias

Dr. Talreja  discusses the 2026 standard of care for treatment of dyslipidemia with new screening guidelines and advanced therapy options.

  • June 12, 2026

Share

Objective:

To discuss the 2026 standard of care for the treatment of dyslipidemia, including new screening guidelines and advanced therapy options as presented by Dr. Talreja.

Approach:
    Key Findings:
    • Introduction of new screening guidelines for dyslipidemia as discussed by Dr. Talreja.
    • Emphasis on advanced therapy options beyond statins as highlighted in the discussion.
    Interpretation:

    Conclusion:

Original Source(s)

2026 Lipid Guidelines Beyond Statins:  Non- Statin Agents to Manage Dyslipidemias

  • June 12, 2026

Related Content

Side Effects: Sour Mouth, Lower BP

Acidic gum beat sugar-free at cranking out nitric oxide from beetroot juice — exactly backward from what test-tube studies predicted. Also this week: a sleep gene that ignores amyloid, and jackfruit sap moonlighting as a bone-building drug delivery system.

Cell Aging May Predict Future Disease

Plasma proteomic models of more than 40 cell types were associated with incident Alzheimer's disease, amyotrophic lateral sclerosis, cancer,  and mortality across three large cohorts.

Triglycerides Linked to Psoriasis Risk

Genetically predicted triglyceride levels were associated with higher odds of psoriasis, while genetically predicted total fatty acid levels were not, in a two-sample Mendelian randomization analysis.